Observation of Curative Effect on 200 Cases of Myasthenia Gravis Treated with Traditional Chinese Medicine

Conference paper
Part of the Lecture Notes in Electrical Engineering book series (LNEE, volume 269)

Abstract

Aim: To observe the curative effect of applying a patented traditional Chinese medicine, namely “a traditional Chinese medicine for treating myasthenia gravis” (assigned Chinese Patent of Invention in 2007), to myasthenia gravis. Methods: 200 cases of myasthenia gravis were collected during 1988–2010. One single course of treatment takes 3 months when using the above-mentioned patented medicine. Such changes of clinical symptoms are noticed before and after treatment: eyelid ptosis, diplopia, weakness, dysarthria, dysphagia, choke cough. We compile scorings according to the quantitative myasthenia gravis (QMG) score system of Myasthenia Gravis Foundation of America. Curative effect: (1) Short-term: the shortest treatment course of this group of cases was 1 month and the longest was 30 months with an normal distribution of 7.21 ± 6.23 months. Among the 200 cases, 104 cases were fully recovered (52 %), 58 cases had obvious effect (29 %), 31 cases (15.5 %) were effective and 7 cases were ineffective (3.5 %), hence the total effective rate was 96.5 % (Table 66.1 in the text). There is a huge difference (P < 0.001, Table 66.2 in the text) between QMG scores of various symptoms before and after treatment (paired-t test). (2) Long-term curative effect: through following up part of the recovered patients (24 cases) for at least half a year and at most 19 years with an average period of 5.72 years, the patients can still participate in normal work or housework without recurrence. Conclusion: The curative effect of 200 cases of myasthenia gravis treated by this patent traditional Chinese medicine was satisfied during 1988–2010.
Table 66.1

Curative effect of all classes (case, %)

Classification

N

Cured

Markedly effective

Effective

Ineffective

Class I

78(39)

47(23.5)

17(8.5)

12(6)

2(1)

ClassII

ClassIIa

19(9.5)

10(5)

7(3.5)

2(1)

0(0)

ClassIIb

23(11.5)

11(5.5)

9(4.5)

3(1.5)

0(0)

ClassIII

ClassIIIa

14(7)

6(3)

6(3)

2(1)

0(0)

ClassIIIb

48(24)

26(13)

14(7)

6(3)

2(1)

ClassIV

ClassIVa

5(2.5)

1(0.5)

1(0.5)

3(1.5)

0(0)

ClassIVb

13(6.5)

3(1.5)

4(2)

3(1.5)

3(1.5)

Total

200(100)

104(52)

58(29)

31(15.5)

7(3.5)

Table 66.2

Comparison of scores of all symptoms before and after treatment (Paired t-test)

Symptom

 

Case

Average

Standard deviation

t value

P value

Left ptosis

Before therapy

174

2.94

0.33

41.37

<0.001

 

After therapy

174

0.42

0.75

  

Right ptosis

Before therapy

165

2.95

0.29

40.55

<0.001

 

After therapy

165

0.42

0.77

  

Diplopia

Before therapy

90

1.00

0.00

43.74

<0.001

 

After therapy

90

0.04

0.21

  

Dysarthria

Before therapy

66

1.00

0.00

20.29

<0.001

 

After therapy

66

0.14

0.35

  

Dysmasesis

Before therapy

70

1.00

0.00

39.26

<0.001

 

After therapy

70

0.04

0.20

  

Dysphagia

Before therapy

63

1.00

0.00

24.27

<0.001

 

After therapy

63

0.10

0.30

  

Suffocated by water

Before therapy

47

1.00

0.00

46.00

<0.001

 

After therapy

47

0.02

0.15

  

Difficulty in raising one’s head

Before therapy

19

1.00

0.00

18.00

<0.001

 

After therapy

19

0.05

0.23

  

Dyspnea

Before therapy

16

1.00

0.00

15.00

<0.001

 

After therapy

16

0.06

0.25

  

Lassitude

Before therapy

69

1.00

0.00

47.73

<0.001

 

After therapy

69

0.03

0.17

  

Keywords

Myasthenia gravis Chinese medicine 

Notes

Acknowledgments

This work was supported by Jilin province science and technology development plan No.20080718.

References

  1. 1.
    Skeie GO, Aarli JA (2003) Muscle autoantibodies in subgroups of myasthenia gravis pstients. J Neurol 247: 369–375Google Scholar
  2. 2.
    Thanvi BR, Lo (2004) TCN.Update on myasthenia gravis. Fellowship Postgrad Med 80(950):690–700Google Scholar
  3. 3.
    Juel VC (2004) Myasthenia gravis: managementof myasthenic crisis and perioperative care. Semin Neurol 24:7581CrossRefGoogle Scholar
  4. 4.
    Li L, Zhang L (2008) Diagnosis and treatment of myasthenia gravis. Chin Arch Tradit Chin Med 26:2375–2377Google Scholar
  5. 5.
    Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of america. Neurology 55(1):16–23CrossRefGoogle Scholar
  6. 6.
    Ministry of Health of the People’s Republic of China, Guiding principles for clinical study of new Chinese medicines, Ministry of Health of the People’s Republic of China, Beijing, China 1995:213–216Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Traditional Chinese MedicineChina Changchun UniversityChangchunChina
  2. 2.Shenyang Research Institute of Traditional Chinese MedicineShenyangChina

Personalised recommendations